Abstract
Objective
This study investigated the phenomenon known as the healthy user bias, by equating hormone therapy (HT) use (past or current) with healthy user status.
Methods
Data from the Survey of Midlife in the United States (MIDUS) were used to indentify predictors of HT use. The unique MIDUS data include psychological, demographic, health-related, and behavioral variables as well as history of HT use. Predictors of HT use were combined to derive propensity scores, describing the likelihood that a woman was an HT user, based on her psychological, demographic, physical, and behavioral profile (i.e., likelihood of being a healthy user) as opposed to her actual use of HT. Finally, cognitive performance on an executive function test was examined in women stratified by propensity score.
Results
Using a multiple logistic regression model, nine variables emerged as predictors of HT use. The nine variables were used to estimate the propensity or conditional probability of using HT for each subject; resultant propensity scores were ranked and divided into tertiles. Women in the highest tertile demonstrated shorter median response latencies on a test of executive function than women who did not use HT.
Conclusions
From an array of psychological, medical and behavioral variables, nine emerged as predictors of HT use. If validated, these features may serve as a means to estimate the phenomenon known as the healthy user bias. Moreover, these data suggest that the degree to which a woman fits a model of a healthy user, may influence cognitive response to HT.
Keywords: Hormone Therapy, Healthy User, Cognition, Menopause, Selection Bias, Executive Functioning
INTRODUCTION
Prior to the publication of findings from two Women's Health Initiative (WHI) ancillary studies, the WHI Memory Study1–4 (WHIMS) and the WHI Study of Cognitive Aging5 (WHISCA), it was widely believed that hormone therapy (HT) use could reduce a woman's risk for dementia by 50%.6–8 This belief was predicated in large part on observational data from longitudinal case-control and cohort studies. In contrast, data from the large, randomized, controlled WHIMS and WHISCA trials revealed adverse cognitive effects and increased risk of dementia for women age 65 and older who were administered a widely-used form of oral HT, conjugated equine estrogen (CEE). The phenomenon referred to as the healthy-user bias was frequently cited as an explanation for the dramatic reversal in findings (e.g., Barrett-Conner et al.,9 Prentice et al.10). Specifically, the healthy-user bias purports that women who use HT during the menopausal transition are systematically different (i.e., healthier) than women who do not use HT; moreover, it is the fundamental differences between HT-users and non-users, and not the exposure to HT, that results in HT's seemingly beneficial health effects, such as fewer cardiovascular risk factors and a reduced risk for dementia found in observational studies.
While the healthy user bias is thought to be a serious threat to study validity, contributing to past misconceptions about HT, it is only loosely and inconsistently operationalized as a research construct. The difficulty in defining the healthy user bias may lie in the fact that sources of bias are multifactorial. For example, behavioral features, such as exercising, not smoking, and regularly consulting with a medical provider; and psychological features such as optimism, sense of control, and proactive behaviors are all alleged to be characteristics of a “healthy user”. Another source of selection bias pertaining to healthy users are differences in access to HT, such that only healthy women who regularly visit a physician would be prescribed HT; whereas women in poor health, those already on several medications, or those with a shortened life expectancy may be less likely to be prescribed a potentially protective medication. These features along with the demographic characteristics of being well-educated and in higher socioeconomic strata culminate in a multifaceted picture of the healthy user, who is allegedly more engaged, physically fit, articulate, adherent to medical advice, and psychologically well than her non-user counterpart.
Data from the Survey of Midlife in the United States (MIDUS) include psychological, behavioral and demographic variables, as well as data on HT use from a large population-based sample. In combination, the data provide a unique opportunity to examine the multiple components theoretically associated with the healthy user construct. Using this comprehensive dataset, we characterized the healthy user bias as it applies to women opting to use HT. In other words, the use of HT was equated with the healthy user phenomenon. In doing so, we attempted to define the demographic, personality, and behavioral characteristics of the healthy-user, by optimally identifying relevant predictors of HT use from a large pool of potential predictors. Variables predicting HT use i.e., healthy user status were used in a subsequent analysis to develop a propensity score. The propensity score would then represent the likelihood of being a healthy user, regardless of whether a women was actually using HT or not. We examined the cognitive performance of women after stratifying for healthy-user status. Overall, we hypothesized that the characteristics indentified as predictors of HT use would coincide with the characteristics traditionally portrayed as features of healthy users. Moreover, we predicted that even after accounting for the healthier user status, cognitive effects related to use versus nonuse of HT would be evident.
METHODS
Participants
Data were obtained from the second wave of MIDUS data collection (MIDUS 2). Participants in this large population-based survey with metropolitan over-samples of non-institutionalized are English-speaking adults, now aged 35 to 86. The intent of the MIDUS project is to investigate patterns, predictors, and consequences of midlife development using a comprehensive array of physical, psychological, and social indicators. The second wave of data collection, MIDUS 2, occurred between January 2004 and January 2006 and included a telephone interview, two self-administered questionnaires mailed, and cognitive testing by telephone. Details of methods employed to ensure maximum follow-up are provided in an online manual.11 From the original MIDUS sample (N=7,108), 4,963 participants completed the telephone interview, resulting in a longitudinal retention rate of 70% (75% response rate when adjusted for mortality). Of telephone respondents, 81% (N=4,032), returned the two self-administered questionnaires and 85% (N=4205) completed the 45 minute telephone cognitive testing. Altogether, a variety of data were collected, including information on demographics, psychological and physical health status, cognition, lifestyle choices, attitudes, and health-related behaviors. Further information on the MIDUS 2 sample and study methods are available at study's data website.12
Groups: Report of Menopausal Status and HT Exposure
The study analyses presented here included only postmenopausal women with complete menopausal status and HT exposure data. While the MIDUS 2 study was not specifically designed to assess women's history of HT use, responses on self-administered questionnaires were used to determine women's menopausal status and exposure to HT. If a respondent indicated that she had stopped menstruating in the last year, she was asked to select a reason why from a list of choices (e.g., menopause, hysterectomy, etc.) and to provide the approximate year of her last menstrual period. To clarify perimenopausal status, women were asked about the regularity of their menstrual periods and if they experienced menopausal symptoms. Women next reported their current or past use of HT. If they had used HT, they indicated their reasons for taking the medication, using a list of options, and provided the dates of initiation and (if applicable) discontinuation of the medications. These data were systematically interrogated to ensure that women were accurately categorized, such that any inconsistencies in the participants' reports were identified and clarified through a review of their responses in total.
Based on their responses, postmenopausal women were categorized into three main groups: Never Users (n=782), Past Users (n=506), or Current Users (n=315). Figure 1 describes the subject selection process. The exclusion of study participants with missing data (described in Figure 1) resulted in a final analytical sample size of 1,189 for the multivariate logistic analyses.
Measures
Variables were selected for possible inclusion in the model predicting HT use if previous published analyses 1) included a variable as a confounder or covariate in analyses (e.g., BMI, smoking, vitamin use, diabetes;13), or 2) revealed the variable to be predictive of HT use (e.g., level of exercise,14 socioeconomic status15). Additionally, some variables were included based on a well-justified but hypothesized relationship to the healthy user phenomenon (e.g. psychological well being). We intended the first stage of variable selection to be highly inclusive. All variables considered for inclusion are listed below, and described in detail in Supplementary Table A (See Table, Supplemental Digital Content 1, http://links.lww.com/MENO/A14). Of note, for the present study, our primary interest was to identify variables predicting HT use, not to obtain estimates of the population values for these variables. Therefore, our analyses did not use case weights to correct for differential selection probabilities and non-response.
Demographic and Anthropometric Variables
Demographic data included age, marital status, highest level of education completed, self-identify ethnicity (Hispanic v. Non-Hispanic), and race. For analyses, White and Asian participants were combined and compared to Black/African American, Native American and self-described “Other” racial category. Socioeconomic status was estimated using a log transformed reported household annual income (log income). Anthropometric data included Body Mass Index (BMI) and waist-to-hip ratios. Further details regarding these variables are provided in Supplementary Table A (See Table, Supplemental Digital Content 1, http://links.lww.com/MENO/A14).
Psychological and Personality Variables
A range of variables measuring psychological and personality characteristics, either empirically or theoretically linked to the healthy user bias were selected for inclusion in the model predicting HT use. Each is described in Supplementary Table A (See Table, Supplemental Digital Content 1, http://links.lww.com/MENO/A14). Briefly, these variables evaluated a participant's perceived control over her health (health locus of control; HLOC-Self and HLOC-Others);16 her sense of agency or perceived control;17 self-described level of conscientiousness;17 optimism;18 and self esteem.19 Additionally, six variables from the Psychological Well-Being (PWB) Scale20 were included: Autonomy, Environmental Mastery, Personal Growth, Positive Relations, Purpose in Life, and Self Acceptance. While there is correlation between the six PWB scales, factor analyses demonstrate that they measure distinct constructs.20, 21 Moreover, the scales differentially associate with biological processes.22
Mood, Level of Satisfaction and Self-Evaluation of Health
Mood and outlook characteristics of participants were considered in the model. Described in Supplementary Table A (See Table, Supplemental Digital Content 1, http://links.lww.com/MENO/A14), specific variables included positive and negative affect subscales from the Positive and Negative Affect Schedule23 (PANAS); depression and anxiety scores from the Composite International Diagnostic Interview – Short Form;24 a rating of overall life satisfaction;25 and a single item assessing self-evaluated physical health that has been shown to be a robust predictor of health outcomes.26
Health Related Behaviors
Several variables assessing health-related behaviors were selected to evaluate the degree to which women engaged in health-maintenance activities. These included a participant's use of vitamins and supplements; her access to, or utilization of routine medical, dental and optical care; her physical and mental activity; and her use of cigarettes and alcohol. Methods describing how each variable was derived are provided in Supplementary Table A (See Table, Supplemental Digital Content 1, http://links.lww.com/MENO/A14).
Physical Health and Medical History
Indicators of current physical and past medical history were investigated as possible predictors of HT use, i.e., the healthy use bias. Details on how these were derived are provided in Supplementary Table A (See Table, Supplemental Digital Content 1, http://links.lww.com/MENO/A14). Specifically, women's answers to questions about two common chronic conditions (high blood pressure and diabetes) were included in the model; along with number hospitalizations in the last year; number of medications; an estimate of physical disability due to health; and past history of stroke, heart attack, head injury or cancer.
Cognitive Variables
The Brief Test of Adult Cognition by Telephone (BTACT) was administered to MIDUS 2 participants, having been found to demonstrate sound psychometric properties and to offer data equivalent to those obtained using face-to-face data collection.27 The battery consists of tests from five cognitive domains sensitive to age and illness-associated changes in cognition, including measures of verbal memory, working memory, executive function, reasoning, and processing speed. While combined summary scores were available, we selected the only speeded executive function task to examine the potential effects of HT on cognition. As reported previously, evidence suggests that the cognitive effects of HT are not global, but rather domain specific.28
Thus, the most challenging and only timed task administered was selected for analyses. The Stop and Go Switch Task (SGST) assesses the ability of participants to switch between two conditional tasks. Under the Normal response condition, participants were to say “go” in response to an examiner reading the word “green,” and “stop” in response to the word “red.” Conversely, under the Reverse condition, they were instructed to provide the opposite response: say “stop” to the word “green” and “go” to the word “red”. Two single-task sets were administered initially; the first being a Normal response condition, the second a Reverse response condition. A third set was administered with the conditions switching between Normal and Reverse at random intervals, referred to as a Mixed-Task set.
Four variables from the SGST test were selected for analyses: 1) median reaction time under the Normal condition (Normal RT), 2) median reaction time under the Reverse condition (Reverse RT), 3) median reaction time for Mixed-Tasks items wherein a condition switch occurred (Normal to Reverse or Reverse to Normal; referred to here as Mixed-Switch RT), and 4) median reaction time from the Mixed-Task trial wherein a condition switch did not occur (Mixed-Nonswitch RT). For each of the last two variables, Mixed-Switch RT and Mixed-Nonswitch RT, additional variables characterizing aspects of performance within each task were available for follow-up analyses. These included: 1) the median reaction time from Normal and Reverse condition trials occurring immediately after a condition switch occurred (Mixed-Switch Normal Switch RT and Mixed-Switch Reverse Switch RT), and 2) median reaction times from Normal and Reverse condition occurring without a switch in conditions (Mixed-Switch Normal Nonswitch RT and Mixed-Switch Reverse Nonswitch RT).
Statistical Methods
Based on previous publications investigating the association between HT use and cognitive outcomes, forty-eight variables were selected as possible predictors of HT use, i.e., potential qualities of a healthy-user. As a first step in reducing the number of variables included in analyses (Step 1), each of the 48 potential predictors was examined individually for its univariate association with HT use (Never v. Past or Current Use). Chi-squared tests were used to determine the statistical significance of the association between categorical variables and HT use. Univariate logistic regression models predicting HT use were selected to examine the statistical association between continuous predictors and HT.
In the next stage of analysis, the P-values associated with each univariate test were ranked and variables with a significance level of P ≤ 0.10 were selected for inclusion in multivariate logistic regression models to predict HT use (Step 2), the goal being to reduce the number of variables without overly limiting the number of potential predictors. Given the potential effect of multicollinearity on parameter estimation, we examined the strength of the associations among all pairs of candidate predictors using Pearson's product-moment correlations. The magnitude of the correlations ranged from 0.002 to 0.764. To minimize multicollinearity effects and efficiently manage the large number of predictors in the model, we used SAS PROC SCADGLIM, Version 1.1 (http://methodology.psu.edu) as a variable selection method for the multiple logistic (or generalized-linear) model.29 This automated variable selection procedure employs a penalized likelihood approach known as smoothly clipped absolute deviation (SCAD) estimator to adjust the likelihood function. The SCAD penalty is the preferred selection process in the presence of collinearity and highly dimensional data compared to other penalized regression approaches such as the least absolute shrinkage and selection operator (LASSO) and ridge regression.30 The Bayesian Information Criterion (BIC) was used as a criterion for final model selection.31 We also examined model sensitivity, specificity, and receiver operating characteristic (ROC) curves to interpret results.
Finally, using the prediction model derived in Step 2, we estimated the propensity or conditional probability of using HT for each subject given a vector of relevant covariates. The resultant propensity scores (i.e., probabilities were ranging from 0 to 1) were ranked and sub-divided into tertiles. In an exploratory analysis, the cognitive performance for women in each of the tertiles was examined by regressing cognitive scores on HT use status while covarying for age and education level (Step 3).
RESULTS
Of the 1603 postmenopausal or perimenopausal women included in Step 1 analysis, 1023 (63.8%) had undergone or were currently experiencing natural menopause. Conversely, 740 (46.2%) women reported undergoing surgical menopause. The mean age of the women included in the Step 1 analysis was 60.7 (SD = 10.3) years. All but 8.7% of the participants completed at least a High School education. In general, participants exhibited low levels of depression and anxiety symptoms, rated their health as good to excellent and viewed themselves as conscientious and optimistic. Table 1 provides a summary of the samples characteristics in HT Users, including the groups Past and Current Users, and Never users.
Table 1.
Never User | Past User | Current User | Combined Past and Current Users | Significance: Never Users v Past or Current Users | |||||
---|---|---|---|---|---|---|---|---|---|
Variables | N | N | N | N | p-value | ||||
Demographic and Anthropometric Variables | |||||||||
Age in years, mean (SD) | 782 | 59.8 (11.2) | 506 | 62.7 (9.1) | 315 | 59.5 (9.4) | 821 | 61.5 (9.3) | 0.01 |
Education, N(%) ≥ High School degree | 782 | 704 90.0% | 505 | 472 (93.5%) | 314 | 285 (90.8%) | 819 | 757 92.4% | 0.40 |
Marital Status, N(%) married | 781 | 455 (58.2%) | 506 | 319 (63.0%) | 315 | 220 (69.8%) | 821 | 539 (65.7%) | 0.01 |
Annual household income, mean K (SD) | 782 | 65.7 (51.5) | 506 | 69.0 (51.7) | 314 | 73.3 (53.5) | 820 | 70.7 (52.4) | 0.06 |
Race, N(%) non-Caucasian | 777 | 77 (9.9%) | 505 | 27 (5.3%) | 314 | 18 (5.7%) | 819 | 45 (5.5%) | <0.01 |
Body Mass Index, mean (SD) | 740 | 28.1 (6.7) | 475 | 27.7 (6.2) | 295 | 27.1 (5.1) | 770 | 27.4 (5.8) | 0.04 |
Waist to Hip Ratio, mean (SD) | 713 | 0.9 (0.1) | 468 | 0.8 (0.1) | 291 | 0.8 (0.1) | 759 | 0.8 (0.1) | 0.01 |
Psychological and Personality Variables | |||||||||
Optimism, mean total of responsesa (SD) | 779 | 22.8 (5.1) | 502 | 23.7 (4.8) | 314 | 23.7 (4.9) | 816 | 23.7 (4.8) | <0.01 |
Self Esteem, mean total of responsesa (SD) | 779 | 36.7 (7.7) | 501 | 38.0 (7.4) | 315 | 37.9 (7.5) | 816 | 37.9 (7.4) | <0.01 |
Autonomyb, mean total of responsesa (SD) | 781 | 37.0 (7.3) | 505 | 36.2 (7.2) | 315 | 36.1 (7.1) | 816 | 36.2(7.1) | 0.03 |
Environmental Masteryb, mean total of responsesa (SD) | 781 | 37.6 (7.8) | 505 | 38.2 (7.6) | 315 | 38.3 (7.9) | 816 | 38.2 (7.7) | 0.10 |
Personal Growthb, mean total of responsesa (SD) | 781 | 38.3 (7.3) | 505 | 39.2 (6.6) | 315 | 39.1 (7.3) | 816 | 39.2 (6.9) | 0.02 |
Positive Relationsb, mean total of responsesa (SD) | 781 | 41.2 (7.1) | 505 | 42.2 (6.4) | 315 | 41.8 (6.9) | 816 | 42.0 (6.6) | 0.02 |
Purpose in Lifeb, mean total of responsesa (SD) | 781 | 37.7 (7.2) | 505 | 38.8 (6.8) | 315 | 38.9 (7.0) | 816 | 38.8 (6.9) | <0.01 |
Self Acceptanceb, mean total of responsesa (SD) | 781 | 37.5 (8.8) | 505 | 38.3 (8.2) | 315 | 38.4 (8.2) | 816 | 38.4 (8.2) | 0.05 |
Mood, Level of Satisfaction and Self-Evaluation Variables | |||||||||
Life Satisfaction, mean responsea (SD) | 782 | 7.6 (1.7) | 506 | 7.7 (1.6) | 315 | 7.8 (1.6) | 821 | 7.8 (1.6) | 0.04 |
Self rated health, N(%) rating health as ≥ Good | 782 | 646 (82.6%) | 506 | 432 (85.4%) | 315 | 270 (85.7%) | 821 | 702 (85.5%) | 0.10 |
Health Related Behaviors | |||||||||
Reports regular use of Multivitamins, N(%) | 782 | 420 (53.7%) | 506 | 346 (68.4%) | 315 | 219 (69.5%) | 821 | 565 (68.8%) | <0.01 |
Reports regular use of Vitamin C, N(%) | 782 | 195 (24.9%) | 506 | 168 (21.5%) | 315 | 90 (28.6%) | 821 | 258 (31.4%) | <0.01 |
Reports regular use of Calcium, N(%) | 782 | 315 (40.3%) | 506 | 310 (61.3%) | 315 | 185 (58.7%) | 821 | 495 (60.3%) | <0.01 |
No. of physical exams/year, N(%) reporting 1–2 | 584 | 321 (55.0%) | 483 | 308 (63.8%) | 283 | 179 (63.3%) | 766 | 487 (63.6%) | <0.01 |
No. of dental exams/year, N(%) reporting 1–2 | 566 | 341 (60.2%) | 466 | 332 (71.2%) | 276 | 201 (72.8%) | 742 | 533 (71.8%) | <0.01 |
No. of eye exams/year, N(%) reporting 1–2 | 557 | 301 (54.0%) | 459 | 287 (62.5%) | 265 | 165 (62.3%) | 724 | 452 (62.4%) | <0.01 |
Frequency of mental activities, mean scorea (SD) | 762 | 16.6 (5.3) | 494 | 17.5 (5.0) | 306 | 17.2 (5.1) | 800 | 17.4 (5.0) | <0.01 |
Alcohol use, N(%) reporting light to moderate use | 746 | 593 (79.5%) | 492 | 418 (85.0%) | 308 | 253 (82.1%) | 800 | 671 (83.9%) | 0.04 |
Physical Health and Medical History | |||||||||
Diabetes, N(%) experience or treated for condition | 782 | 91 (11.6%) | 506 | 50 (9.9%) | 315 | 17 (5.4%) | 821 | 67 (8.2%) | 0.02 |
Physical limitations, mean scorea (SD) | 742 | 18.2 (8.3) | 487 | 18.7 (8.4) | 306 | 19.1 (8.8) | 793 | 18.9 (8.5) | 0.10 |
N of prescription medications, mean number (SD) | 748 | 1.7 (1.9) | 486 | 2.1 (1.7) | 308 | 2.8 (1.7) | 794 | 2.3 (1.7) | <0.01 |
Higher scores indicate higher levels of the variable being measured
Scale from the Psychological Well Being Inventory
cPANAS: Positive and Negative Affect Schedule
dScore reflects frequency of activity in two settings (work and leisure) and across two time periods (Winter and Summer)
Univariate analyses conducted with 48 candidate variables suggested that 26 characteristics of the sample were predictive of HT use when examined alone (Step 1). Table 1 summarizes each of the 26 variables, as well as the age and educational status of participants, including variable sample sizes, prevalence (for categorical variables), means (for continuous variables), and the P-values obtained in the univariate tests. (Supplementary Table B, Supplemental Digital Content 2, http://links.lww.com/MENO/A15 lists the same information for the 22 variables not selected as predictors of HT use, i.e., P-value of univariate analyses > 0.10). Notably, the age of Users (Current and Past) differed from Nonusers. While the difference was statistically significant, this variable was not included in predictor models, as it was thought to reflect a cohort difference. Specifically, older women were more likely to be Past Users, as opposed to Current or Never Users, probably because women well-past menopause were encouraged to discontinue HT after the WHI findings were published.
When the 26 candidate predictors were entered into a multiple logistic regression model predicting HT use, employing the SCAD variable selection approach, the best model (BIC=1262) produced nine statically significant predictors of group membership (Never User v. Past or Current User). Table 2 lists the variables surviving Step 2 analysis. Overall the Area Under the Curve (AUC) obtained when the nine variables listed in Table 2 were used to predict HT Use (Never v. Past or Current) was 0.73.
Table 2.
Variable | B | S.E. | P-value | Odds Ratio |
---|---|---|---|---|
Demographic and Anthropometric Variables | ||||
Race | ||||
Caucasian and Asian groups combined (R) | ||||
African American | −1.26 | 0.39 | <0.01 | 0.29 |
Other | 0.00 | 0.34 | 1.00 | 1.00 |
Waist to Hip Ratio | −2.36 | 0.85 | 0.01 | 0.09 |
Annual household income | 0.22 | 0.07 | <0.01 | 1.24 |
Psychological and Personality Variables | ||||
Self Esteem | 0.03 | 0.01 | <0.01 | 1.03 |
Autonomy | −0.04 | 0.01 | <0.01 | 0.97 |
Mood, Level of Satisfaction and Self-Evaluation Variables | ||||
Health Related Behaviors | ||||
Reports regular use of Calcium | 0.78 | 0.13 | <0.01 | 2.18 |
N of physical exams/year | ||||
0 routine visits/year (R) | ||||
1–2 routine visits/year | 0.83 | 0.21 | <0.01 | 2.29 |
3 or more routine visits/year | 0.74 | 0.23 | <0.01 | 2.09 |
Physical Health and Medical History | ||||
Diabetes, experience or treated for condition | −1.00 | 0.22 | <0.01 | 0.37 |
N of prescription medications | 0.36 | 0.05 | <0.01 | 1.44 |
Constant | −1.65 | 1.20 | 0.17 | 0.19 |
(R) - Reference category of the variable
Finally, cognitive variables measuring speeded executive function were examined in combination with HT propensity scores. Women's likelihood of using HT was characterized as either a low, medium or high propensity to be an HT user i.e., a healthy user. Women in the low and middle ranges demonstrated no significant difference in their performance on the SGST variables. However, women in the highest tertile (i.e., women embodying the healthy user characteristics) demonstrated shorter median response latencies on the SGST Mixed-Switch trials, than women who did not use HT. Table 3 lists the median response times and p-values for cognitive task comparison between HT users and never users in the highest stratum of propensity scores. A follow up comparison of the type of switch task that occurred, revealed that past or current users of HT were faster than never users on tasks requiring them to switch from the Reverse condition to the Normal condition. Their performance when switching from the Normal condition to the Reverse condition was not different based on HT use.
Table 3.
Table 3.A. Four global performance scores | ||||
---|---|---|---|---|
B | SE | t | p-value | |
Median reaction time under the Normal condition (Normal RT) | ||||
(Constant) | 0.891 | 0.332 | 2.680 | 0.008 |
Age | 0.008 | 0.005 | 1.642 | 0.101 |
Education | 0.002 | 0.018 | 0.110 | 0.913 |
HT Use | −0.181 | 0.102 | −1.782 | 0.085 |
Median reaction time under the Reverse condition (Reverse RT) | ||||
(Constant) | 0.856 | 0.088 | 9.684 | <0.001 |
Age | 0.004 | 0.001 | 2.972 | 0.003 |
Education | −0.012 | 0.005 | −2.650 | 0.008 |
HT Use | −0.028 | 0.027 | −1.030 | 0.304 |
Median reaction time from the Mixed-Task trial wherein a condition switch did not occur (Mixed-Nonswitch RT) | ||||
(Constant) | 0.877 | 0.080 | 10.930 | <0.001 |
Age | 0.004 | 0.001 | 3.372 | 0.001 |
Education | −0.012 | 0.004 | −2.833 | 0.005 |
HT Use | −0.026 | 0.025 | −1.042 | 0.298 |
Median reaction time for Mixed-Tasks items wherein a condition switch occurred (Mixed Switch Normal to Reverse or Mixed Switch Reverse to Normal) | ||||
(Constant) | 0.917 | 0.178 | 5.140 | <0.001 |
Age | 0.009 | 0.003 | 3.573 | <0.001 |
Education | −0.013 | 0.009 | −1.320 | 0.188 |
HT Use | −0.132 | 0.055 | −2.416 | 0.016 |
Table 3.B. Subsets of performance scores for Mixed-task Switch Tasks | ||||
---|---|---|---|---|
B | SE | t | p-value | |
Median reaction time for Mixed-Tasks items wherein the condition switched from Reverse to Normal (Mixed-Switch Normal Switch RT) | ||||
(Constant) | 0.812 | 0.261 | 3.114 | 0.002 |
Age | 0.014 | 0.004 | 3.650 | <0.001 |
Education | −0.004 | 0.014 | −0.299 | 0.765 |
HT Use | −0.198 | 0.079 | −2.492 | 0.030 |
Median reaction time for Mixed-Tasks items wherein the condition switch from Normal to Reverse (Mixed-Switch Reverse Switch RT) | ||||
(Constant) | 0.661 | 0.061 | 10.837 | <0.001 |
Age | 0.004 | 0.001 | 5.117 | <0.001 |
Education | −0.007 | 0.003 | −2.273 | 0.024 |
HT Use | −0.022 | 0.019 | −1.161 | 0.246 |
DISCUSSION
From a list of candidate variables, describing a variety of psychological, behavioral, mood, and health status characteristics, nine participant features emerged as predictors of HT use. Specifically, HT users were more likely to be White or Asian; had had higher incomes; had lower waist-to-hip ratios, received regular physical exams (1–2 per year), were likely to use calcium supplements, and were less likely to have diabetes than women who never used HT. HT users reported slightly more use of prescription medications than non-users (mean of 2 to 3 medications compared to 1.7 in non-users). Additionally, HT users in our study exhibited higher self esteem and reported a small but significantly lower level of autonomy than non-users.
HT use, more than the use of other medications, has been proposed as a marker for the phenotype referred to as the healthy-user (e.g., Barrett-Conner et al.,9 Prentice et al.10). For this reason, being an HT user was equated in this study with being a healthy user. These analyses were motivated by concerns that any association between HT use and cognitive function in postmenopausal women may be artifacts of the healthy user bias (i.e., HT users are reported to be psychologically and physically healthier, to have better access to preventative care, are more likely to engage in healthy behaviors than nonusers); as such, the superior cognitive performance of HT users was attributed to selection bias rather than direct effects of HT use. In contrast, our results suggest that women possessing the characteristics of a “healthy user” who used HT demonstrated an advantage on an executive functioning task over similar women who never used HT. If confirmed, these data suggest that HT confers beneficial cognitive effects, but only for women in optimal health.
A number of previous studies have examined how HT users differ from non-users. For example, women who used HT in the Nurse's Health Study (NHS) were at lower risk for cardiovascular events (i.e, myocardial infarction and death due to coronary heart disease). However, they were also thinner, ate healthier diets, engaged in more exercise, and used less alcohol than women who did not use HT.32 Other studies specifically examined how HT users and non-users differed, consistently reporting that women prescribed HT at menopause were less obese, more physically active, and better educated, and in contrast to the NHS findings, were more likely to use alcohol.33, 34 Also influencing the likelihood of being an HT user was age, type of menopause (surgical v. natural) and the diagnosis of osteoporosis, with users being younger, more likely to have experienced surgical menopause and to carry a diagnosis of osteoporosis.33 Similar relationships between HT use, and demographic and behavioral characteristics emerge when European cohorts were examined. While less commonly prescribed in European countries, HT use was positively associated with education, socioeconomic status, nulliparity or lower birth rates, non-immigrant status, lower Body Mass Index, better diet, regular exercise, surgical menopause and osteoporosis.35–37 Interestingly, the characteristics of user and non-users did not appear to change markedly following the publication of data suggesting HT was potentially harmful for cardiovascular health.38
The emerging story that women who were prescribed HT were systematically different than never users, led Matthews et al.39 to ask if users were indeed healthier than non-users. In other words, a selection bias occurs in HT prescription practices, such that women using HT fit a profile of a healthy user. Unlike other studies describing the HT user, Matthews et al. were able to include both health and psychological factors in their investigation, and found that HT users exhibited healthier cardiovascular risk profiles prior to HT use, described themselves as possessing Type A personality features, and were more likely to be aware of and to express their emotions, motives, and symptoms of stress.
While a number of studies examined characteristics of HT uses, none had access to the wide array of psychological, personality, demographic, and health status variables available in the MIDUS data set. Given the richness of the MIDUS data we may be able to more fully characterize the healthy user bias by examining a greater variety of potential characteristics of HT users than past studies examining a more limited set of predictors.
Overall, the findings of the present analyses portray a similar profile of HT users as that of Matthews et al.39 For example, compared to non-users, women in the MIDUS study who used HT had higher incomes, were more likely White or Asian, had lower waist-to-hip ratios, and reported higher self esteem. Consistent with them being healthy, HT users in our study received regular physical exams (1–2 per year), were likely to use calcium supplements, and were less likely to have diabetes than women who never used HT. Perhaps because of their regular medical care, HT users reported more use of prescription medications than non-users. Another finding contrasted earlier reports; specifically, HT users in our study reported a small but significantly lower level of autonomy than non-users. These data were collected shortly after the publication of the WHI findings;40, 41 and the time periods of HT use or non-use reported by respondents straddle the dates of the WHI publications. The finding that women prescribed HT describe themselves as less autonomous than non-users may reflect a reaction to shifts in public perception of HT, such that women describing themselves as autonomous addressed their menopausal transition by opting not to use HT.
Another aspect of the current study involved using the nine variables predictive of HT use to develop healthy user propensity scores for each subject. In doing so, we were able to characterize the propensity of individual women to be HT users or healthy users, regardless of whether they used or did not use HT. Per our theory, women with high propensity scores possess more of the qualities of a healthy user than do women with low propensity scores. An exploratory analysis, comparing cognitive performance on a demanding executive function task suggested that only women possessing more qualities of the healthier user may demonstrate cognitive differences based on their HT exposure. Specifically, the difference in performance was noted on the Stop and Go Switch Task. Women were instructed that they were to provide either concordant (normal) or discordant (reverse) responses to the stimuli “Stop” and “Go,” saying either “red” to stop or “green” to stop depending on the instructions (normal v. reverse). In sets that required women to switch between the normal and reverse conditions (mixed-task), women who were past or current users of HT were responded faster than non users when a switch occurred. The advantage in speed appeared to occur when the switch involved moving from the more difficult condition (reverse switch) or to the easier condition (normal switch).
The current study's limitations need to be acknowledged. First it may be inaccurate to equate the healthy user with an HT user. While related, the two concepts likely diverge in some regards. For example, HT use would describe only female healthy users; and it may not apply to non-US and non-European populations or to selected sub-groups within these primarily White, affluent cultures, where medical care is relatively easily accessible. Importantly, this cross-sectional analysis does not imply a causal relationship between HT use and healthy user variables, only an association. Another limitation was the large number of participants who were missing data for one or more of the twenty-six variables included in the Propensity models (Step 2 of analyses; See Figure 1). Over 400 women were excluded for this reason, most of whom were never-users. This would also limit the generalizability of our models, and may have reduced power to detect the relationships between the variables and HT use. There may be biases introduced by selection of only a subset of the MIDUS sample (i.e., women for whom menopausal status and HT use were available.) Finally, the analysis of cognitive data was considered exploratory and p-values were not corrected for multiple comparisons. This increases the risk for Type 1 error, such that the suggestion of cognitive benefits with HT may be inaccurate, reflecting spurious or random findings.
Still, the present study may help clarify the contradictory findings regarding HT use, cognitive function, and risk for dementia. As noted, it was once widely believed that hormone therapy (HT) use could reduce a woman's risk for dementia by up to 50%.6–8 In sharp contrast, findings from WHIMS,1–4 suggested cognitive harm and increased risk for dementia. To clarify the contradiction, some proposed a theoretical “critical window” during which HT needed to be applied in order to be protective (e.g. Resnick & Henderson;42 Sherwin43). Specifically, in observational studies, most use of HT occurred at or shortly after menopause, as opposed to initiating use after a decade or more of no exposure to hormones (endogenous or exogenous), as was the case for many WHI participants. Per the critical window hypothesis, use outside the critical time frame around menopause, could have no effect or could in fact be harmful. The data from the present study suggest an additional explanation. Specifically, the beneficial effects of HT may be sufficiently small, such that illnesses like diabetes, and life long exposure to stress and poverty overwhelm any potential benefit of HT medications. On the other hand, for women in good health, whose socioeconomic status and psychological health are optimized, HT may confer some cognitive benefits.
There is less equivocation about the biological effects of endogenous hormones compared to exogenous HT. For example, cardiac event rates are low in premenopausal women; however, the rates rise dramatically after menopause.44 Similarly, an earlier age of menopause is associated with increase risk for dementia in women with Down's syndrome.45 The confusion regarding exogenous hormones administered as HTs highlights the pressing need to reconcile the contradictory science regarding the neurobiological and cognitive effects of menopausal HT. In the meantime, dramatic reversals followed by continued equivocation in scientific opinions have left women confused and mistrustful about any reports on the neurobiological effects of HT. The present study offers insight as to how the healthy-user bias might be defined, and how these intrinsic differences between HT users and non-users could influence the potential cognitive benefits of HT. Continued exploration of the healthy user bias and other key differences between observational and clinical trial data (e.g., when in relation to menopause did HT exposure occur) is needed in order to address and overcome the inconsistencies in findings.
CONCLUSIONS
The present study offers insights into the nature of the healthy user bias and how this influential factor may have contributed to past misconceptions about HT. By equating the concepts of HT user and healthy user, this study offers a means to estimate a person's propensity to be a healthy user. These data suggest that the degree to which a person fits a model of healthier user status, may influence cognitive response to HT.
Supplementary Material
Acknowledgements
This is GRECC Manuscript number: 2011–10. The authors gratefully acknowledge the assistance of Dr. Gleason's Masters in Clinical Investigation Committee members: Molly Carnes, MD, MS and Carol Ryff, PhD. Additionally, we express gratitude to Rachel Hunter-Merrill for her assistance with statistical analyses.
FINANCIAL SUPPORT: None
FUNDING SOURCES: This research was supported by funding from the NIH (K23 AG024302; P50 AG033514).
Footnotes
CONFLICT OF INTEREST/FINANCIAL DISCLOSURE: None
DISCLAIMERS: None
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
REFERENCES
- 1.Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. Jama. 2004 Jun 23;291(24):2947–2958. doi: 10.1001/jama.291.24.2947. [DOI] [PubMed] [Google Scholar]
- 2.Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. Jama. 2003 May 28;289(20):2651–2662. doi: 10.1001/jama.289.20.2651. [DOI] [PubMed] [Google Scholar]
- 3.Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. Jama. 2004 Jun 23;291(24):2959–2968. doi: 10.1001/jama.291.24.2959. [DOI] [PubMed] [Google Scholar]
- 4.Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. Jama. 2003 May 28;289(20):2663–2672. doi: 10.1001/jama.289.20.2663. [DOI] [PubMed] [Google Scholar]
- 5.Resnick SM, Maki PM, Rapp SR, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab. 2006 May;91(5):1802–1810. doi: 10.1210/jc.2005-2097. [DOI] [PubMed] [Google Scholar]
- 6.Miller MM, Monjan AA, Buckholtz NS. Estrogen replacement therapy for the potential treatment or prevention of Alzheimer's disease. Ann N Y Acad Sci. 2001 Dec;949:223–234. doi: 10.1111/j.1749-6632.2001.tb04025.x. [DOI] [PubMed] [Google Scholar]
- 7.Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000;101(3):485–512. doi: 10.1016/s0306-4522(00)00410-3. [DOI] [PubMed] [Google Scholar]
- 8.Fillit HM. The role of hormone replacement therapy in the prevention of Alzheimer disease. Arch Intern Med. 2002 Sep 23;162(17):1934–1942. doi: 10.1001/archinte.162.17.1934. [DOI] [PubMed] [Google Scholar]
- 9.Barrett-Connor E, Grady D, Stefanick ML. The rise and fall of menopausal hormone therapy. Annu Rev Public Health. 2005;26:115–140. doi: 10.1146/annurev.publhealth.26.021304.144637. [DOI] [PubMed] [Google Scholar]
- 10.Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol. 2005 Sep 1;162(5):404–414. doi: 10.1093/aje/kwi223. [DOI] [PubMed] [Google Scholar]
- 11.Ryff C, Almeida D, Ayanian J, et al. National Survey of Midlife. Development in the United States. (MIDUS II), 2004–2006. ICPSR 4652. Field Report for MIDUS 2 Longitudinal Sample. http://www.icpsr.umich.edu/icpsrweb/NACDA/studies/28683/detail.
- 12.Midlife Development in the United States (MIDUS II), 2004–2006. http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/4652?archive=ICPSR&q=midus+2. Updated Last Updated Date.
- 13.Kang JH, Weuve J, Grodstein F. Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women. Neurology. 2004 Jul 13;63(1):101–107. doi: 10.1212/01.wnl.0000132522.13574.67. [DOI] [PubMed] [Google Scholar]
- 14.Isaacs AJ, Britton AR, McPherson K. Why do women doctors in the UK take hormone replacement therapy? J Epidemiol Community Health. 1997 Aug;51(4):373–377. doi: 10.1136/jech.51.4.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Petitti DB, Freedman DA. Invited commentary: how far can epidemiologists get with statistical adjustment? Am J Epidemiol. 2005 Sep 1;162(5):415–418. doi: 10.1093/aje/kwi224. discussion 419–420. [DOI] [PubMed] [Google Scholar]
- 16.Wallston BS, Wallston KA, Kaplan GD, Maides SA. Development and validation of the health locus of control (HLC) scale. J Consult Clin Psychol. 1976 Aug;44(4):580–585. doi: 10.1037//0022-006x.44.4.580. [DOI] [PubMed] [Google Scholar]
- 17.Lachman ME, Weaver SL. The Midlife Development Inventory (MIDI) Personality Scales: Sacle construciton and score: Technical Report. 1997. [Google Scholar]
- 18.Scheier MF, Carver CS. Optimism, coping, and health: assessment and implications of generalized outcome expectancies. Health Psychol. 1985;4(3):219–247. doi: 10.1037//0278-6133.4.3.219. [DOI] [PubMed] [Google Scholar]
- 19.Rosenberg M. Society and the adolescent self-image. Princeton University Press; Princeton, N.J.: 1965. [Google Scholar]
- 20.Ryff CD, Keyes CL. The structure of psychological well-being revisited. J Pers Soc Psychol. 1995 Oct;69(4):719–727. doi: 10.1037//0022-3514.69.4.719. [DOI] [PubMed] [Google Scholar]
- 21.Ryff CD. In the eye of the beholder: views of psychological well-being among middle-aged and older adults. Psychol Aging. 1989 Jun;4(2):195–201. doi: 10.1037//0882-7974.4.2.195. [DOI] [PubMed] [Google Scholar]
- 22.Ryff CD, Dienberg Love G, Urry HL, et al. Psychological well-being and ill-being: do they have distinct or mirrored biological correlates? Psychother Psychosom. 2006;75(2):85–95. doi: 10.1159/000090892. [DOI] [PubMed] [Google Scholar]
- 23.Mroczek DK, Kolarz CM. The effect of age on positive and negative affect: a developmental perspective on happiness. J Pers Soc Psychol. 1998 Nov;75(5):1333–1349. doi: 10.1037//0022-3514.75.5.1333. [DOI] [PubMed] [Google Scholar]
- 24.Kessler RC, Andrews G, Mroczek D, Ustun B, Wittchen HU. The World Health Organization Composite International Diagnostic Interview Short-Form (CIDI-SF) International Journal of Methods in Psychiatric Research. 1998;7:171–185. [Google Scholar]
- 25.Prenda KM, Lachman ME. Planning for the future: a life management strategy for increasing control and life satisfaction in adulthood. Psychol Aging. 2001 Jun;16(2):206–216. [PubMed] [Google Scholar]
- 26.Myint PK, Luben RN, Surtees PG, et al. Relation between self-reported physical functional health and chronic disease mortality in men and women in the European Prospective Investigation into Cancer (EPIC-Norfolk): a prospective population study. Ann Epidemiol. 2006 Jun;16(6):492–500. doi: 10.1016/j.annepidem.2005.04.005. [DOI] [PubMed] [Google Scholar]
- 27.Tun PA, Lachman ME. Telephone assessment of cognitive function in adulthood: the Brief Test of Adult Cognition by Telephone. Age Ageing. 2006 Nov;35(6):629–632. doi: 10.1093/ageing/afl095. [DOI] [PubMed] [Google Scholar]
- 28.Asthana S. Estrogen and cognition: a true relationship. JAGS. 2004;52:316–318. doi: 10.1111/j.1532-5415.2004.52078.x. [DOI] [PubMed] [Google Scholar]
- 29.Dziak J, Lemmon D, Li R, Huang L. PROC SCADGLIM User's Guide (Version 1.1) The Methodology Center, Penn State; University Park: 2010. [Google Scholar]
- 30.Fan J, Li R. Variable selection via nonconcave penalized likelihood and its oracle properties. Journal of the American Statistical Association. 2001;96(456):1348–1360. [Google Scholar]
- 31.Schwarz G. Estimating the dimension of a model. Annals of Statistics. 1978;6:461–464. [Google Scholar]
- 32.Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985 Oct 24;313(17):1044–1049. doi: 10.1056/NEJM198510243131703. [DOI] [PubMed] [Google Scholar]
- 33.Cauley JA, Cummings SR, Black DM, Mascioli SR, Seeley DG. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol. 1990 Nov;163(5 Pt 1):1438–1444. doi: 10.1016/0002-9378(90)90602-4. [DOI] [PubMed] [Google Scholar]
- 34.Egeland GM, Kuller LH, Matthews KA, Kelsey SF, Cauley J, Guzick D. Premenopausal determinants of menopausal estrogen use. Prev Med. 1991 May;20(3):343–349. doi: 10.1016/0091-7435(91)90033-z. [DOI] [PubMed] [Google Scholar]
- 35.Persson I, Bergkvist L, Lindgren C, Yuen J. Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: evidence of confounding by exposure characteristics. J Clin Epidemiol. 1997 May;50(5):611–618. doi: 10.1016/s0895-4356(97)00004-8. [DOI] [PubMed] [Google Scholar]
- 36.Ringa V, Ledesert B, Gueguen R, Schiele F, Breart G. Determinants of hormonal replacement therapy in recently postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 1992 Jul 24;45(3):193–200. doi: 10.1016/0028-2243(92)90084-c. [DOI] [PubMed] [Google Scholar]
- 37.Parazzini F, La Vecchia C, Negri E, Bianchi C, Fedele L. Determinants of estrogen replacement therapy use in northern Italy. Rev Epidemiol Sante Publique. 1993;41(1):53–58. [PubMed] [Google Scholar]
- 38.Parazzini F. Trends of determinants of hormone therapy use in Italian women attending menopause clinics, 1997–2003. Menopause. 2008 Jan-Feb;15(1):164–170. doi: 10.1097/gme.0b013e318057782b. [DOI] [PubMed] [Google Scholar]
- 39.Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 1996 May 15;143(10):971–978. doi: 10.1093/oxfordjournals.aje.a008678. [DOI] [PubMed] [Google Scholar]
- 40.Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Jama. 2002 Jul 17;288(3):321–333. doi: 10.1001/jama.288.3.321. [DOI] [PubMed] [Google Scholar]
- 41.Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321–333. doi: 10.1001/jama.288.3.321. [DOI] [PubMed] [Google Scholar]
- 42.Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease: a critical time. JAMA. 2002 Nov 6;288(17):2170–2172. doi: 10.1001/jama.288.17.2170. [DOI] [PubMed] [Google Scholar]
- 43.Sherwin BB. Estrogen and memory in women: how can we reconcile the findings? Horm Behav. 2005 Mar;47(3):371–375. doi: 10.1016/j.yhbeh.2004.12.002. [DOI] [PubMed] [Google Scholar]
- 44.Hu FB, Stampfer MJ, Manson JE, et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med. 2000 Aug 24;343(8):530–537. doi: 10.1056/NEJM200008243430802. [DOI] [PubMed] [Google Scholar]
- 45.Coppus AM, Evenhuis HM, Verberne GJ, et al. Early Age at Menopause is Associated with Increased risk of Dementia and Mortality in Women with Down Syndrome. J Alzheimers Dis. 2009 Oct 8; doi: 10.3233/JAD-2010-1247. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.